No­var­tis' San­doz reshuf­fles an­tibi­ot­ic sup­ply chain in EU as field faces a short­age of in­vest­ment

While much of the fo­cus in man­u­fac­tur­ing has shift­ed away from an­tibi­otics, a di­vi­sion of No­var­tis is putting mon­ey in­to a Eu­ro­pean ex­pan­sion. San­doz will shuf­fle its an­tibi­ot­ic pro­duc­tion in Eu­rope by adding ca­pa­bil­i­ties at two of its plants and phas­ing out man­u­fac­tur­ing at an­oth­er by 2024, the com­pa­ny said.

The ex­pan­sion will in­clude more than $122 mil­lion to add new tech­nol­o­gy to make oral amox­i­cillin, an API in peni­cillin, and al­low the com­pa­ny to use its Kundl, Aus­tria plant as a hub for its end-to-end an­tibi­otics sup­ply chain in Eu­rope. It will al­so pour $61 mil­lion in­to its Palafolls site in Spain to in­crease peni­cillin pro­duc­tion ca­pac­i­ty, the com­pa­ny said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER